Acertis Pharmaceuticals Licenses U.S. Commercial Rights to Licart® from IBSA

Expands Pain Management Portfolio with Next-Generation Topical NSAID Therapy RALEIGH, N.C. — January 5, 2026 — Acertis Pharmaceuticals, a specialty pharmaceutical company focused on delivering